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Studies with the myogenic basic helix-loop-helix and
MADS box factors suggest that efficient transactivation
is dependent on the recruitment of the steroid receptor
coactivator (SRC) and the cofactors p300 and p300/CBP-
associated factor. SRCs have been demonstrated to re-
cruit CARM1 (coactivator-associated arginine methyl-
transferase-1), a member of the S-adenosyl-L-methio-
nine-dependent PRMT1–5 (protein-arginine N-
methyltransferase-1–5) family, which catalyzes the
methylation of arginine residues. This prompted us to
investigate the functional role of CARM1/PRMT4 during
skeletal myogenesis. We demonstrate that CARM1 and
the SRC cofactor GRIP-1 cooperatively stimulate the
activity of myocyte enhancer factor-2C (MEF2C). More-
over, there are direct interactions among MEF2C,
GRIP-1, and CARM1. Chromatin immunoprecipitation
demonstrated the in vivo recruitment of MEF2 and
CARM1 to the endogenous muscle creatine kinase pro-
moter in a differentiation-dependent manner. Further-
more, CARM1 is expressed in somites during embryo-
genesis and in the nuclei of muscle cells. Treatment of
myogenic cells with the methylation inhibitor adeno-
sine dialdehyde or tet-regulated CARM1 “antisense” ex-
pression did not affect expression of MyoD. However,
inhibition of CARM1 inhibited differentiation and abro-
gated the expression of the key transcription factors
(myogenin and MEF2) that initiate the differentiation
cascade. This work clearly demonstrates that the argi-
nine methyltransferase CARM1 potentiates myogenesis
and supports the positive role of arginine methylation
in mammalian differentiation.
Nuclear hormone receptors have served as prototypic models
of coactivator recruitment (1). One current hypothesis suggests
that the steroid receptor coactivator (SRC)1 class of cofactors
(2, 3) function as primary coactivators by binding directly to
ligand-regulated transcription factors. Transcriptional activa-
tion also involves the subsequent recruitment of secondary
coactivators such as p300, p300/CBP-associated factor, and the
protein methyltransferases PRMT1 protein-arginine N-
methyltransferase-1–5 and CARM1/PRMT4 (4–6). CBP/p300
and PCAF can acetylate histones and others components of the
transcription complex, which leads to chromatin remodeling
and initiation. PRMT1 and CARM1 are members of the S-
adenosyl-L-methionine-dependent PRMT family, each of which
catalyzes the methylation of arginine residues on specific pro-
teins. At least five distinct members have been described, in-
cluding PRMT1, PRMT2, PRMT3, CARM1/PRMT4, and
PRMT5/JBP1 (Refs. 7–10 and references therein). A growing
number of proteins, including RNA-binding proteins, contain
-NG-monomethylarginine and asymmetric-NG,NG-dimethyl-
arginine residues. Furthermore, the PRMT family interacts
with a range of proteins, including heterogeneous nuclear ri-
bonucleoproteins, Np13 mRNA export protein, poly(A)-binding
protein, TIS21, Jak2 receptor tyrosine kinase, SRCs, interfer-
on-/ receptors, interleukin enhancer-binding factor, etc.
Hence, the evidence to date implicates PRMT proteins as es-
sential components of RNA processing and trafficking, recep-
tor-mediated signaling, and transcription (11).
Arginine methylation in proteins is a common post-transla-
tional modification. Furthermore, PRMT1, a predominantly
nuclear protein, methylates arginine residues in proteins con-
taining RGG and RXR motifs, including fibrillarin (the
sclerodoma antigen) (12) and the fragile X mental retardation
gene protein (directly involved in fragile X syndrome) (13).
Arginine methylation is emerging as an additional layer of
control in the regulation of chromatin remodeling and gene
expression.
The involvement of SRC-2/GRIP-1 (a cofactor that recruits
CARM1/PRMT4) in a functional complex that coactivates myo-
genic transcription factors (15) prompted us to investigate the
expression and functional role of the CARM1 methyltrans-
ferase during skeletal muscle differentiation (myogenesis).
CARM1 can methylate histone H3 in vitro, whereas PRMT1
methylates histone H4 (4). PRMT1 prefers to methylate argi-
nine residues in glycine-rich regions of RNA-binding proteins;
in contrast, CARM1 has little or no activity with the substrates
preferred by PRMT1. However, PRMT1 and CARM1 function
synergistically to transactivate nuclear receptor-mediated gene
expression in an SRC-dependent manner (6). However, despite
this information, the recent cloning of the prmt genes, and the
determination of the methyltransferase core crystal structure
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of the PRMT proteins (14), the function of these methyltrans-
ferases in differentiation, development, and disease remains
obscure.
The PRMT proteins are recruited by C-terminal activation
domain-2 of the SRC GRIP-1, whereas p300 interacts with
activation domain-1 in the C terminus (5). We report here that
the CARM1 and S-adenosyl-L-methionine (AdoMet)-dependent
methylation are necessary for the latter stages of biochemical
and morphological skeletal muscle differentiation and that
CARM1 functions as a critical secondary coactivator for myo-
cyte enhancer factor-2 (MEF2)-mediated gene expression in an
SRC-2/GRIP-1-dependent manner.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—Proliferating CH310T1/2 cells were
kept in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 20 and 10% fetal calf serum (FCS), respectively. To induce C2C12
cells to differentiate, confluent myoblast culture medium was changed
to differentiation medium (DMEM supplemented with 2% horse se-
rum). C2C12 cells normally started to differentiate 48–72 h after the
serum withdrawal. Transient transfections were performed with a mix-
ture of two liposomes (DOTAP and DOSPER (Roche Molecular Bio-
chemicals)) as described previously (15). Luciferase activity was as-
sayed using a Luclite kit (Packard Instrument Co.) according to the
manufacturer’s instructions, and relative luciferase units were meas-
ured in a Wallac Trilux 1450 Microbeta luminometer.
Immunostaining of Myocytes and Fluorescence Immunohistochemis-
try—Cells were fixed and stained as described previously (15). Immu-
nohistochemical analysis was then performed using a monoclonal anti-
body directed against the fast isoform of the major thick filament
protein skeletal myosin heavy chain (clone MY32, Sigma). This proce-
dure is described in detail (15).
For fluorescence immunohistochemistry analysis, C2C12 cells were
grown on cover slips held in six-well dishes. Cells were washed with
phosphate-buffered saline (PBS) once and then fixed in 100% methanol
at 20 °C for 5 min. After fixation, cells were washed once with PBS
and then quenched in PBS containing 50 mM NH4Cl to avoid the
deleterious effect of the methanol on the antibodies. Cells were incu-
bated in blocking solution (0.2% fish skin gelatin and 0.2% bovine
serum albumin diluted in PBS) at room temperature for 10 min and
subsequently treated with primary antibody (1:200) in blocking solution
at room temperature for 30 min. Finally, the cells were washed with
PBS prior to incubation with BODIFY-conjugated secondary antibodies
(diluted 1:2000; Molecular Probes, Inc.) in blocking solution at room
temperature for 30 min. Visualization of nuclei was achieved with
4,6-diamidino-2-phenylindole staining (1:2000 dilution in PBS) at room
temperature for 10 min after the secondary antibody incubation.
Gal4 and Mammalian Two-hybrid Assays in Pluripotent C3H10T1/2
Cells—C3H10T1/2 cells were passaged into 12-well plates and trans-
fected at 60–80% confluence with 1000 ng of reporter G5E1b-luc and
330 ng of Gal4-MEF2C or the Gal4 DNA-binding domain alone in the
presence and absence of GRIP-1 and/or CARM1 by the DOTAP/
DOSPER-mediated method (15) in DMEM supplemented with 10%
FCS. After 16–24 h, the medium was replaced, and the cells were
harvested 24–48 h after transfection for the assay of luciferase activity.
Mammalian two-hybrid assays were performed in 12-well plates of
JEG-3 cells (60–70% confluence) cotransfected with 1 g of reporter
G5E1b-luc, 0.3 g of Gal4 chimeras, and 0.3 g of VP16 chimeras (in the
presence and absence of cofactors (GRIP-1 and/or CARM1)) in 1 ml of
DMEM containing 5% charcoal-stripped FCS by the DOTAP/DOSPER-
mediated procedure as described previously (15). Each experiment rep-
resented at least two sets of independent triplicates to overcome the
variability inherent in transfections (24).
Construction of Stable Cell Lines Expressing tet/dox-regulated
CARM1 Antisense Expression—C2C12 cells were transfected at 40%
confluence using the liposome-mediated method as described above for
transient transfection. The tetracycline-repressible pUHD (tet-off) plas-
mid (5–10 g) was transfected into cells grown in a 10-cm Petri dish.
After transfection, cells were kept in normal growth medium for 24 h to
allow them to recover and for high expression of NEO before starting
G418 selection. Monoclonal cell lines were isolated after 14 days of
selection in growth medium containing 800 g/ml G418 (Invitrogen).
Monoclonal cell lines expressing transfected constructions were further
characterized for response to tetracycline repression by transient trans-
fection of reporter constructs containing luciferase under the regulation
of tetracycline response elements in the presence of tetracycline (100
g/ml) or doxycycline (1 g/ml). Clones that showed a response to
tetracycline were selected and used for the stable transfection of
pUHD10.3-CARM1, which expresses antisense CARM1. The stable
cloning of the second plasmid (pUHD10.3-CARM1) was similar to that
of the first (pUHD), except that hygromycin was used as selection
antibiotic instead of G418. After selection in hygromycin for 2–3 weeks,
monoclonal cells were picked and passaged in 10-cm dishes for RNA
isolation. Clones expressing antisense CARM1 were verified by North-
ern blotting first and Western blotting later.
GST Pull-down Assays and Western and Immunoprecipitation Anal-
yses—GST and GST fusion proteins were expressed in Escherichia coli
strain BL21 and purified by glutathione-agarose affinity chromatogra-
phy as described previously (15). Total RNA from C2C12 myoblasts and
myotubes was prepared using the acid/guanidinium/thiocyanate-based
method (30). Briefly, cells were harvested in PBS containing 5 mM
EDTA and then lysed in 4 M guanidinium thiocyanate, 25 mM sodium
citrate (pH. 7.0), 0.5% Sarkosyl, and 0.1 M -mercaptoethanol as de-
scribed previously (15). Northern blotting and hybridization were per-
formed by standard techniques (15). Nuclear proteins were isolated by
resuspending cells in 0.5–2 ml of TM buffer (10 mM Tris (pH 7.4), 2 mM
MgCl, and 5 mM dithiothreitol) freshly supplemented with protease
inhibitors and incubated on ice for 5–10 min. The cells were spun down
at 2000 rpm for 10 min at 4 °C. The supernatant was discarded, and the
cells were frozen and thawed twice to break the cell membranes. The
broken cells were resuspended in 0.5 ml of TM buffer and incubated on
ice for 10 min, followed by spinning at 2000 rpm for 10 min at 4 °C. The
supernatant was aspirated for analysis of cytosolic protein, and 0.5 ml
of nuclear extract buffer (20 mM Tris, 400 mM KCl, 2 mM EDTA, 2 mM
MgCl, 1 mM dithiothreitol, and 10% glycerol) freshly supplemented with
protease inhibitors was added to resuspend the cells and then incubated
on ice for 60–90 min. The cells were vigorously vortexed every 10 min
during this incubation to maximize the extraction efficiency. Cell debris
was cleared by centrifugation at 15,000 rpm for 20 min at 4 °C, and the
supernatant was dialyzed against PBS at 4 °C to reduce the salt con-
centration. After dialysis, the protein concentrations were determined
by the Bradford dye method. Western and immunoprecipitation analy-
ses were performed as described previously (15).
RESULTS
CARM1 Directly Interacts with MEF2C in Vitro, but Not with
MyoD and Myogenin—The SRC GRIP-1 has been demon-
strated to recruit the coactivator-associated methyltransferase
CARM1/PRMT4, which functions as a secondary cofactor in
nuclear receptor-mediated transactivation of gene expression.
CARM1 directly interacts with GRIP-1 and acts as a secondary
coactivator for transcription in an SRC-dependent manner.
Recently, GRIP-1 has been found to be necessary for skeletal
muscle differentiation in culture; furthermore, GRIP-1 directly
interacts with the MADS (MCM1-agamous deficiens-serum re-
sponse factor) box factor MEF2C and the basic helix-loop-helix
(bHLH) factor myogenin (in an E2A-dependent manner) and
increases their activity (15). MEF2 and myogenin function
cooperatively to regulate the latter stages of skeletal muscle
differentiation and the activation of contractile protein
transcription.
Hence, we examined the ability of CARM1 to interact with
GRIP-1 (a positive control) and the myogenic factors MEF2C,
MyoD, and myogenin. We tested this using a biochemical ap-
proach, the in vitro GST pull-down assay, to examine potential
interactions among CARM1, GRIP-1, MEF2C, MyoD, and myo-
genin. Glutathione-agarose-immobilized GST-CARM1 was
tested for direct interaction with in vitro 35S-radiolabeled na-
tive GRIP-1, MEF2C, myogenin, and MyoD. We observed, as
expected (4), that GRIP-1 interacted with CARM1. Surpris-
ingly, MEF2 interacted with CARM1 directly; however, myo-
genin and MyoD did not interact with CARM1 (Fig. 1A).
To rigorously validate the physical association of CARM1
and MEF2C in an additional assay, CARM1 and MEF2C were
translated in a rabbit reticulocyte lysate. We observed that
immunoprecipitation of a rabbit reticulocyte lysate pro-
grammed with CARM1 and MEF2C in the presence and ab-
sence of GRIP-1 with an antibody directed against MEF2C
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resulted in co-immunoprecipitation of CARM1 (Fig. 1B). This
demonstrates that these two proteins directly interact. How-
ever, the MEF2 interaction with CARM1 was weak compared
with the efficient MEF2/GRIP-1 interaction.
We further verified the interaction of CARM1 with MEF2C
by examining the ability of GST-myogenin, GST-myogenin-
bHLH, GST-MEF2C-MADS-(1–57), and GST-MEF2C-Cter-
(224–465) to interact with in vitro 35S-radiolabeled native
CARM1. As expected, CARM1 did not interact with GST-bHLH
chimeras, but interestingly required the C-terminal region of
MEF2C for interaction (Fig. 1C). We verified that this was not
an artifact of a nonfunctional GST-MADS chimera by demon-
strating interaction with GRIP-1 (but not with CARM1) in a
GST-pull down assay (Fig. 1D). The above experiments dem-
onstrate the interaction among MEF2C, GRIP-1, and CARM1
and are in accordance with GRIP-1-mediated coactivation of
MEF2-mediated transcription (15).
CARM1/PRMT4 Directly Interacts with the C-terminal Re-
gion of MEF2C—To further support the specificity of the inter-
action between the carboxyl-terminal region of MEF2C and
CARM1, we examined the ability of a number of GST-MEF2C
fusion chimeras containing various functional subdomains of
MEF2C immobilized on glutathione-agarose beads (i.e. native
GST-MEF2C-(1–465), GST-MEF2C-(1–57), GST-MEF2C-(58–
465), GST-MEF2C-(90–465), GST-MEF2C-(91–223), and GST-
MEF2C-(224–465). CARM1 showed a strong interaction with
GST-MEF2C (native) relative to GST alone. Deletion of the
MADS box (required for the interaction with GRIP-1) or the
MEF2 domain did not compromise the interaction with
CARM1. This was consistent with the inability of CARM1 to
interact with GST-MEF2C-(1–57). Furthermore, CARM1 failed
to interact with GST-MEF2C-(91–223), which encodes the N-
terminal activation domain of MEF2C. However, CARM1 in-
teracted very efficiently with the C-terminal region of MEF2C
between amino acids 224 and 465 (Fig. 2A). This segment
encodes the C-terminal activation domain of MEF2C between
amino acids 247 and 327. The above experiments verify the
direct interaction between MEF2C and CARM1.
MEF2C, GRIP-1, and CARM1 Interact in a Cellular Con-
text—To further characterize transcriptional regulation by
MEF2C, we investigated whether these transcriptional cofac-
tors interact with MEF2C in a cellular context in vivo. Protein/
protein interaction assay systems were initially developed in
yeast and further refined for the study of protein/protein inter-
actions in transfected mammalian cells. In these experiments,
the yeast Gal4 DNA-binding domain was fused to MEF2C and
expressed in transfected cells with GRIP-1 linked to the trans-
activation domain of herpes simplex virus VP16. Because co-
activation of MEF2-dependent transcription by GRIP-1 was
augmented by the secondary coactivator CARM1, we used a
modified mammalian two-hybrid system (Fig. 2B) to further
investigate the molecular basis of the MEF2/GRIP-1-mediated
activation. We examined the effect of CARM1 expression on the
interaction between Gal4-MEF2 and VP16-GRIP-1. Significant
transactivation of a luciferase reporter gene downstream of
Gal4-binding sites fused to the E1b promoter was achieved only
when the coexpressed proteins physically interacted (Fig. 2B).
Chimeric Gal4-MEF2C regulated transcription of the
G5E1b-luc reporter (as previously demonstrated above) (Fig.
2B). Gal4-MEF2C alone activated transcription (10-fold) rel-
ative to the Gal4 DNA-binding domain. We then examined the
ability of coexpressed VP16-GRIP-1 to enhance reporter gene
expression in this mammalian two-hybrid system. We observed
that VP16-GRIP-1 effectively and significantly induced tran-
scription by 5–7-fold, resulting in a 50–70-fold increased trans-
activation of gene expression.
We observed that addition of the CARM1 expression vector
further increased transactivation of gene expression by MEF2
in a GRIP-1-dependent manner. In conclusion, the mammalian
two-hybrid experiments demonstrate that the MEF2GRIP-1
complex interacts with CARM1 in the cellular context and
suggest that the mechanism of activation involves physical
association.
The Coactivator-associated Arginine Methyltransferase
FIG. 1. MEF2C interacts with GRIP-1. A, glutathione-agarose-
immobilized GST and GST-CARM1 proteins were incubated with 35S-
radiolabeled full-length GRIP-1, MEF2C, MyoD, or myogenin. The in-
put lanes represent 10% of the total protein. B, shown are the results
from co-immunoprecipitation of CARM1 and GRIP-1 with MEF2C.
CARM1, GRIP-1, and MEF2C expression plasmids were transcribed/
translated in a rabbit reticulocyte lysate and mixed as indicated. Re-
ticulocyte-produced proteins were then immunoprecipitated (IP) with
anti-MEF2 antibody (Ab), and the 35S-labeled proteins were analyzed
by SDS-PAGE. CARM1, GRIP-1, and MEF2C were co-immunoprecipi-
tated with anti-MEF2 antibodies. C, the MADS domain does not inter-
act with CARM1. Glutathione-agarose-immobilized GST, GST-myoge-
nin, GST-myogenin-bHLH, GST-MEF2C-MADS, and GST-MEF2C-
Cter proteins were incubated with 35S-radiolabeled full-length
CARM1. The input lanes represent 10% of the total protein. D, glu-
tathione-agarose-immobilized GST and GST-MEF2C-MADS proteins
were incubated with either 35S-radiolabeled GRIP-1 or CARM1. The
input lanes represent 10% of the total protein.
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CARM1/PRMT4 Coactivates MEF2C-mediated Transcrip-
tion—The biochemical experiments presented above suggest
that CARM1 interacts with MEF2C in complex with the SRC
GRIP-1. Furthermore, CARM1 functions as a secondary cofac-
tor to enhance transactivation by nuclear hormone receptors in
an SRC-dependent manner (4, 5). Because the SRC cofactor
GRIP-1 interacts with and modulates the activity of MEF2C
(which cooperates with the myogenic bHLH proteins in the
activation of contractile protein gene expression) (15), we ex-
amined the ability of CARM1 to regulate MEF2-dependent
gene expression.
We stably transfected pluripotent CH310T1/2 cells with an
MEF2-dependent luciferase reporter with three tandem copies
of the MEF2-binding site upstream of a basal E1b promoter
(Fig. 3A). This cell line was then transiently transfected with
different combinations of MEF2C, GRIP-1, and CARM1. We
observed maximal transactivation of gene expression upon co-
transfection of MEF2C, GRIP-1, and CARM1. These experi-
ments demonstrate that MEF2C, the SRC GRIP-1, and the
secondary cofactor CARM1 synergistically coactivate MEF2C-
mediated transactivation of an MEF2-dependent reporter.
The Coactivator-associated Arginine Methyltransferase
CARM1 Increases MEF2 Activity in a GRIP-1-dependent Man-
ner—The experiments presented above suggest that the SRC
cofactor GRIP-1 and the secondary cofactor CARM1 coactivate
MEF2C-mediated transcription. Because MEF2C can activate
transcription directly and/or by protein/protein interaction
through tethering to other DNA-bound factors, we examined
the effect of CARM1 expression on MEF2C-mediated transac-
tivation in the Gal4 hybrid system in the presence and absence
of GRIP-1 (Fig. 3B). In these assays, the activity of MEF2C is
independent of its binding to its cognate DNA motif, the A/T-
rich MEF2 site. If CARM1 regulates the transcriptional activ-
ity, then the potential of the Gal4-myogenic factor fusions to
transactivate gene expression should be greatly increased in
this assay (Fig. 3B).
We subsequently transfected pluripotent C3H10T1/2 cells
with Gal4-MEF2C and the G5E1b-luc reporter in the presence
and absence of CARM1 and GRIP-1 expression vectors. G5E1b-
luc contains five copies of the Gal4-binding site placed up-
stream of a minimal E1b promoter. Transfection of Gal-MEF2C
alone modestly induced transcription relative to the Gal4 DNA-
binding domain; this level of activity was significantly stimu-
lated (5–7-fold) by the simultaneous expression of GRIP-1 and
CARM1 (Fig. 3B), as was observed with the MEF2-dependent
luciferase reporter genes (Fig. 3A). CARM1-mediated coactiva-
tion was dependent on the presence of GRIP-1; CARM1 expres-
sion in the absence of GRIP-1 failed to increase the activity of
MEF2C. We similarly observed that CARM1 also mediated
coactivation of MEF2A and MEF2D in the presence of GRIP-1
(data not shown).
CARM1 and MEF2 Are Recruited ”in Vivo“ by the Muscle
Creatine Kinase Promoter in a Differentiation-dependent Man-
ner—Chromatin immunoprecipitation is a sensitive technique
that enables detection of endogenous transcription factors and
cofactors recruited in vivo to promoters under different physi-
ological conditions. We employed this procedure to investigate
the recruitment of MEF2 and CARM1 to the endogenous MEF2-
dependent muscle creatine kinase promoter during skeletal
myogenesis. The mouse myogenic C2C12 cell line was used for
these studies, as they differentiate well in culture and are very
well characterized in terms of MEF2-dependent gene expres-
sion. Soluble chromatin was prepared from proliferating (un-
differentiated) myoblasts cultured in growth medium (DMEM
supplemented with 20% FCS) and from post-mitotic multinu-
cleated myotubes after 72–96 of serum withdrawal in differen-
tiation medium. The samples were immunoprecipitated with
antibodies specific to MEF2 and the cofactor CARM1. The
presence of specific promoters in the immunoprecipitates was
analyzed by PCR using primers designed to amplify the region
spanning the MEF2-binding sites in the muscle creatine kinase
enhancer. Fig. 3C shows that the amount of MEF2 and CARM1
recruited to the muscle creatine kinase promoter increased in
material derived from differentiated cells. This result was not
influenced by chromatin amounts in the myoblast and myotube
inputs confirmed by PCR prior to immunoprecipitation; in fact,
the differentiated sample had less material. The soluble chro-
FIG. 2. The C-terminal region of MEF2C mediates the interac-
tion with CARM1. A, diagrammatic representation showing the
MEF2C regulatory domains. Glutathione-agarose-immobilized GST
and GST-MEF2C proteins were incubated with 35S-radiolabeled full-
length CARM1. Deletion of the C-terminal domain between amino acids
223 and 465 ablated binding to CARM1 in vitro. The input lanes
represent 10% of the total protein. B, diagrammatic representation of
the mammalian two-hybrid assay used to determine the interaction and
cooperativity of CARM1, GRIP-1, and MEF2C in a cellular context.
CARM1 interacted with MEF2 in a GRIP-1-dependent manner. -Fold
activation is expressed relative to luciferase activity obtained after
cotransfection of the Gal4 DNA-binding domain alone, arbitrarily set at
1. TAD I, N-terminal activation domain; TAD II, C-terminal activation
domain; LUC, luciferase.
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matin was also treated with rabbit IgG (nonimmune) as a check
against nonspecific precipitation. These data demonstrate dif-
ferentiation-dependent CARM1 recruitment to the well char-
acterized MEF2-dependent muscle creatine kinase promoter
and provide in vivo evidence for CARM1 function during skel-
etal myogenesis.
CARM1 Is Expressed during Mouse Embryogenesis—Expres-
sion of carm1 during mouse embryo development was studied
by whole-mount in situ hybridization. Antisense RNA probes
were prepared from carm1 cDNA spanning the 3-coding region
and the 3-untranslated region that is specific to the carm1
gene so as to exclude possible cross-reactivity with other prmt
sequences. At 8.25 days postcoitus, CARM1 expression was
observed in the fore- and hindbrain, neural fold, somites, and
posterior lateral plate (Fig. 4A, panels i and ii). At 8.75 days
postcoitus, CARM1 expression was prominent in the neural
tube and somites (Fig. 4B, panels i and ii). The pattern of
CARM1 expression was consistent with the early expression of
MEF2 proteins in muscle precursor cells and non-myogenic
lineages during mouse embryogenesis (16).
CARM1 mRNA and Protein Are Expressed during Skeletal
Muscle Differentiation—CARM1 is expressed in the skeletal
muscle precursors (i.e. somites) during mouse embryogenesis
and, in cultured cells, modulates the activity of MEF2C, a
critical factor in the activation of contractile protein transcrip-
tion. Hence, we examined the expression and functional role of
CARM1 in muscle differentiation (myogenesis), an ideal para-
digm for analysis of the determinative events that govern the
cells’ decision to divide or differentiate.
Proliferating C2C12 myoblasts were induced to differentiate
biochemically and morphologically into post-mitotic multinu-
cleated myotubes by serum withdrawal in culture over a 72-h
period. The transition from a non-muscle phenotype to a con-
tractile phenotype is associated with the activation/expression
of (i) the myoD gene family (myoD, myogenin, myf-5, and MRF-
4), (ii) the MEF2 MADS box proteins, and (iii) a structurally
diverse group of genes that encode a functional sarcomere
responsible for contraction. The differentiation process is or-
chestrated and dependent on the cooperative interaction be-
tween myogenin and MEF2 (17, 18).
Total RNA was isolated from proliferating myoblasts and
post-mitotic myotubes after 72 h of serum withdrawal and
examined by Northern blot analysis. The CARM1 mRNA was
constitutively expressed in proliferating myoblasts and post-
mitotic differentiated multinucleated myotubes that have ac-
quired a muscle-specific phenotype (Fig. 4C). The hybridization
signal corresponded to the expected transcript size of 3.8 kb.
Total lysate and nuclear extract were isolated from prolifer-
ating myoblasts, confluent myoblasts, and myotubes after 3
days of serum withdrawal. Western analysis of total lysates
with the polyclonal antibody to mouse CARM1 demonstrated
that the CARM1 protein was expressed in myoblasts and myo-
tubes (Fig. 4D). However, Western analysis of nuclear extracts
demonstrated that CARM1 protein levels in the nucleus in-
creased during the differentiation process, reaching a peak in
the post-mitotic myotube cells.
In conclusion, the CARM1 mRNA and protein are expressed
during skeletal muscle differentiation in culture. The expres-
sion pattern of CARM1 and its function as a secondary coacti-
vator through association with the SRC cofactor GRIP-1 (which
interacts with steroid receptors and MEF2) were consistent
with its function as an MEF2 cofactor.
CARM1 Is Expressed in the Nucleus during Skeletal Muscle
Differentiation—The CARM1 mRNA and protein are abun-
dantly expressed during the differentiation of mouse muscle
cells in culture. To detect and analyze the subcellular localiza-
FIG. 3. CARM1 coactivates MEF2-mediated transcription in an
SRC-dependent manner. A, CARM1 coactivates MEF2-mediated
transactivation of a stably integrated MEF2-dependent reporter. The
luciferase reporter composed of three tandem copies of the MEF2-
binding site linked to a basal E1b-luc reporter in pGL3-back was stably
transfected into pluripotent C3H10T1/2 cells. Subsequently, this cell
line was transiently transfected with different combinations of expres-
sion vectors driving MEF2C, GRIP-1, and CARM1 expression. -Fold
activation is expressed relative to the native luciferase activity of the
stably transfected cell population obtained after transient transfection
of the empty expression vector. Activation mediated by vector alone was
arbitrarily set at 1. Transfection results were derived from three inde-
pendent transfections. B, CARM1 potentiates the activity of MEF2C in
a GRIP-1-dependent manner. A diagrammatic representation of the
Gal4 hybrid assay is shown. This assay was used to determine the effect
of CARM1 and GRIP-1 expression on MEF2C transcriptional activity.
CH310T1/2 cells were transfected with a plasmid encoding Gal4-
MEF2C (i.e. the yeast Gal4 DNA-binding domain (DBD) fused in frame
with full-length MEF2C) and a reporter construct in which five copies of
the Gal4-binding site are placed upstream of the minimal E1b promoter
(i.e. G5E1b-luc). C, soluble chromatin was prepared from cultures of
proliferating myoblasts (MB) in growth medium (GM) and from post-
mitotic multinucleated myotubes (MT) in differentiation medium (DM).
Samples were immunoprecipitated (IP) with antibodies specific to
MEF2 and CARM1. The myotube material was also treated with rabbit
IgG to control for nonspecific precipitation of chromatin. Immunopre-
cipitated material was analyzed by PCR using primers designed to
amplify sequences spanning the MEF2-binding sites in the muscle
creatine kinase enhancer as described by Lu et al. (31).
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tion pattern of the steroid receptor secondary coactivator
CARM1, we conducted immunofluorescence staining using
polyclonal anti-CARM1 antibody (catalog number 07-0780, Up-
state Biotechnology, Inc.). CARM1 was endogenously ex-
pressed in low to high confluent proliferating C2C12 myoblasts
grown in high serum (Fig. 5, A and C). The majority of staining
was in the cell nucleus, but there was also significant staining
observed in the cytoplasm. The staining pattern in the nucle-
oplasm was extranucleolar and appeared in prominent nuclear
dots in a punctate pattern. After 72 h of serum withdrawal and
induction of the differentiation program, the CARM1 staining
was almost exclusively localized to the nucleus (Fig. 5, E and
F), with little (if any) staining in the cytoplasm.
The Methyltransferase Inhibitor Adenosine Dialdehyde
Blocks Terminal Muscle Differentiation—To delineate the func-
tional role of the protein-arginine methyltransferase CARM1
in myogenesis and to identify the signal pathway that this
secondary cofactor regulates, we examined the effect of treat-
ment with the methylation inhibitor adenosine dialdehyde on
differentiation. This treatment leads to an accumulation of
methyl-accepting substrates/proteins in hypomethylated
states. Adenosine dialdehyde is an inhibitor of S-adenosylho-
mocysteine hydrolase and can elevate the cellular levels of
S-adenosylhomocysteine, the product inhibitor of methyltrans-
ferases, utilizing AdoMet as the methyl donor.
C2 muscle cells were cultured in growth medium and then
cultured in differentiation medium for 72 h. Mitogen with-
drawal activated the differentiation program. These cells were
compared with cells cultured for 72 in differentiation medium
supplemented with 20 M adenosine dialdehyde (Fig. 6A). The
effect of methyltransferase inhibition at the biochemical level
was assayed by Western analysis of treated (adenosine dialde-
hyde) and untreated cells cultured in differentiation medium
for 72 h. We examined the effect of adenosine dialdehyde treat-
ment on factors involved in determination (e.g. MyoD), differ-
entiation (myogenin and MEF2), and contraction (myosin
heavy chain (MHC)). Furthermore, we assayed GRIP-1 expres-
sion; this SRC cofactor is necessary for skeletal muscle differ-
entiation and interacts with MEF2 and the methyltransferase
CARM1 during steroid receptor-mediated transactivation.
We isolated nuclear extracts from C2 cells cultured in differ-
entiation medium in the presence and absence of adenosine di-
aldehyde. Western analysis was performed with antibodies
against MyoD, myogenin, MEF2, GRIP-1, and MHC. Immuno-
blot analysis (Fig. 6A) demonstrated that adenosine dialdehyde
treatment had no effect on either MyoD or GRIP-1 expression
levels. However, myogenin and MEF2 protein levels were ablated
and dramatically reduced, respectively, after adenosine dialde-
hyde treatment (Fig. 6A). Finally, we examined a later step in the
differentiation program, i.e. the expression of structural proteins
that encode a functional sarcomere and are responsible for the
contractile phenotype. Immunoblot analysis with the monoclonal
FIG. 4. Analysis of CARM1 expression during mouse embryo-
genesis by whole-mount in situ hybridization. A and B, we iso-
lated embryos at 8.25 and 8.75 days postcoitus from the outbred mouse
strain CD1. They were staged by standard morphological criteria. Ex-
pression of CARM1 during mouse embryo development was studied by
whole-mount in situ hybridization. Antisense and sense RNA probes
were prepared from carm1, but not containing any poly(A) sequences, so
as to exclude possible cross-reactivity with other prmt sequences. The
digoxigenin-labeled CARM1 riboprobes were hybridized to whole mouse
embryos isolated at 8.25 days postcoitus (dpc) (A, panels i and ii), and
8.75 days postcoitus (B, panels i and ii). nf, neural fold; s, somite; nt,
neural tube. C, CARM1 mRNA is constitutively expressed during skel-
etal muscle differentiation. Total RNA was isolated from proliferating
myoblasts (PMB; 50% confluent propagated in growth medium) and
from differentiated myotubes after 72 h of serum withdrawal (MT;
propagated in differentiation medium). After blotting, RNA was probed
with 32P-radiolabeled cDNA encoding CARM1, myogenin, and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH). The induction of myoge-
nin mRNA indicated that these cells had undergone terminal differen-
tiation. D, shown are the results from Western analysis of CARM1
levels during skeletal muscle differentiation and in vitro translated
(IVT) Western control. Total cellular lysate and nuclear extracts were
isolated from proliferating myoblasts (PMB), confluent myoblasts
(CMB), and myotubes after 3 days of serum withdrawal (MT). Myo-
blasts were cultured in growth medium, and myotubes were cultured in
differentiation medium.
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antibody directed against the fast isoform of the major thick
filament protein skeletal MHC demonstrated that treated cells
lack the major thick filament sarcomeric protein.
Subsequently, the extent of differentiation was assayed by
immunostaining with the monoclonal antibody directed
against the fast isoform of skeletal MHC. MHC is associated
with the contractile phenotype and was expressed during the
later stages of muscle differentiation (Fig. 6B). The immuno-
histochemistry results dramatically demonstrated that the in-
hibitor ablated morphological differentiation of proliferating
myoblasts into multinucleated myotubes. This suggests that
hypomethylation of proteins significantly compromises (i)
morphological differentiation and formation of post-mitotic
myotubes and (ii) the activation of contractile protein gene(s).
In summary, adenosine dialdehyde treatment revealed that
AdoMet-dependent methylation is necessary for (i) morpholog-
ical differentiation, (ii) activation of essential transcription fac-
tors, and (iii) activation of contractile protein gene(s).
CARM1 Antisense RNA Expression Inhibits Skeletal Muscle
FIG. 5. CARM1 progressively localizes to the nuclei of muscle
cells during differentiation. A and C, CARM1 expression (red) in
increasingly confluent proliferating C2C12 myoblasts grown in growth
medium; E and F, CARM1 in differentiated myotubes after 72 h of
serum withdrawal (i.e. cultured in differentiation medium); B and D,
4,6-diamidino-2-phenylindole-stained nucleus (blue). C2 cells were
grown on cover slides held in six-well dishes. CARM1 immunostaining
(red) of fixed cells was performed with the purified antibody against
CARM1 (residues 595–608 of mouse CARM1). Cells were washed and
incubated with the secondary antibody (Texas Red-conjugated goat
anti-rabbit IgG; 1:2000).
FIG. 6. A, Western analysis of total lysates from both normal C2C12
and adenosine dialdehyde-treated cells after 72 h of serum withdrawal
in the presence and absence of 20 M adenosine dialdehyde (AdOx).
Proteins were detected by Western blotting with 30 g of nuclear
proteins from each sample using a rabbit antibody to MEF2 (C-21,
Santa Cruz Biotechnology) that is generated against MEF2A, but that
cross-reacts with mouse/human MEF2A/C and MEF2D. GRIP-1 pro-
teins were detected by Western blotting with 30 g of nuclear proteins
from each sample using a monoclonal antibody to human GRIP-1/TIF-2
(T73620, Transduction Laboratories) that cross-reacts with the mouse
species. B, immunostaining of untreated and treated (20 M adenosine
dialdehyde) C2C12 cells with a monoclonal antibody directed against
the fast isoform of the major thick filament protein skeletal MHC after
72 h of culture in differentiation medium. Immunohistochemistry re-
vealed that adenosine dialdehyde treatment compromised the activa-
tion of contractile protein gene(s) and formation of post-mitotic
multinucleated myotubes. MHC-positive cells are stained red, and nu-
clei are counterstained blue by Mayer’s hematoxylin solution.
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Cell Differentiation—To delineate the specific functional role of
the CARM1 protein-arginine methyltransferase in myogenesis,
we proceeded to use the tetracycline-off system to express
CARM1 antisense RNA in myogenic cells. We initially trans-
fected proliferating C2C12 myoblasts with a plasmid encoding
the pTet-off tetracycline-regulated transactivator, pUHD.Neor,
which expresses a chimeric fusion protein of amino acids 1–207
of tetR and the C-terminal 130 amino acids of the herpes
simplex virus activation domain. This converts tetR from a
transcriptional repressor to a tetracycline-regulated transacti-
vator that binds to the tet operator (tetO) sequences in the
absence of tetracycline (Fig. 7A). Following G418 selection,
resistant clones were selected and subsequently screened by
transient transfection with a tetracycline-regulated luciferase
reporter. Cell clones that exhibited a high degree of regulated
expression of the reporter and still retained the ability to dif-
ferentiate in culture were selected and subsequently trans-
fected with a tetracycline-dependent cytomegalovirus promoter
(pUHD.10.3-hygr) driving CARM1 antisense expression. Hy-
gromycin-resistant clones were selected and subsequently
screened for a low/zero background of CARM1 antisense ex-
pression in the presence of doxycycline/tetracycline, potential
to differentiate, and high inducibility and expression of CARM1
antisense RNA after tetracycline withdrawal (Fig. 7B).
C2-CARM1 antisense muscle cells were cultured in growth
medium in the presence and absence of doxycycline and then
cultured in differentiation medium in the presence and absence
of doxycycline for 48–72 h (Fig. 7C). We isolated nuclear ex-
tracts from C2 cells cultured in differentiation medium in the
presence and absence of doxycycline. Western analysis was
performed with antibodies against MyoD, myogenin, MEF2,
GRIP-1, and CARM1. Immunoblot analysis (Fig. 7C) demon-
strated that serum withdrawal in the presence of doxycycline
resulted in the expected biochemical changes associated with
muscle differentiation in culture, i.e. increases in MEF2, myo-
genin, GRIP-1, and CARM1. MyoD expression levels remained
constitutive.
Serum withdrawal in the absence of doxycycline induced
CARM1 antisense RNA expression and reduced CARM1 pro-
tein expression dramatically (Fig. 7C). This was substantiated
and highlighted after immunofluorescence analysis of myo-
blasts cultured in growth medium in the presence (Fig. 7D) and
absence (Fig. 7E) of doxycycline. As expected, CARM1 was
expressed in the nucleus in myoblasts cultured in the presence
of doxycycline. However, in the absence of doxycycline, the
CARM1 protein was expressed in a diffuse cytoplasmic manner
at reduced levels in myoblasts (Fig. 7, C and E).
In the absence of doxycycline after 48 and 72 h of serum
withdrawal, the induction of CARM1 antisense expression
completely abrogated the induction of the CARM1, MEF2,
GRIP-1, and myogenin proteins. In contrast, MyoD expression
was unaffected by the cellular knockout of CARM1 expression.
This clearly demonstrates that CARM1 expression is necessary
and potentiates muscle differentiation in a positive manner. In
summary, CARM1 antisense expression reveals that the coac-
tivator-associated arginine methyltransferase activity is neces-
sary for the induction of critical transcription factors and co-
factors associated with terminal differentiation.
DISCUSSION
This study demonstrates that CARM1 is necessary for skel-
etal muscle differentiation. Furthermore, we show that
CARM1 functions as a secondary cofactor for MEF2-mediated
transcription in an SRC-2/GRIP-1-dependent manner in the
regulation of muscle-specific gene expression (Fig. 8). Consist-
ent with these functions, we observed abundant CARM1 ex-
pression in muscle cells and in skeletal muscle precursors
during embryogenesis. CARM1 function and AdoMet-mediated
FIG. 7. A, schematic displaying the es-
sential features of tet-off-regulated gene
expression; B, CARM1 Northern analysis
of stably transfected independent clones
and of the cell line displaying tet-off-in-
ducible antisense CARM1; C, Western
analysis of CARM1, MEF2, GRIP-1,
MyoD, and myogenin levels in the anti-
sense CARM1 (CARM 1-as)-transfected
cells in the presence and absence of doxy-
cycline; D and E, immunofluorescence
and 4,6-diamidino-2-phenylindole analy-
sis of CARM1 expression in proliferating
myoblasts from C2C12 muscle cells trans-
fected with tet-regulated antisense
CARM1 in the presence (D) and absence
(E) of doxycycline (Dox). CMV, cytomega-
lovirus; GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase; GM, growth medi-
um; DM, differentiation medium.
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methylation are critical for myogenesis and suggest that argi-
nine methylation potentiates differentiation. Our observations
are consistent with (i) GRIP-1-mediated coactivation of MEF2-
dependent transcription (15), (ii) direct interaction between
MEF2 and GRIP-1 (15), (iii) SRC-dependent recruitment of
CARM1 during nuclear hormone receptor-mediated transcrip-
tion, and (iv) MEF2 expression during mouse embryogenesis
(16).
SRC and p300 coactivate several different classes of activa-
tors, e.g. NF-B (2, 19) and the myogenic bHLH and MADS box
factors. For example, CBP/p300 and GRIP-1 are coactivators
for MyoD and MEF2 during myogenic differentiation (summa-
rized in Fig. 8) (15, 20–23). CARM1 was previously shown to
function as a secondary coactivator for nuclear hormone recep-
tors (4, 5), i.e. CARM1 is recruited indirectly by nuclear recep-
tors through its interaction with GRIP-1. Our data suggest that
CARM1 also functions a secondary cofactor for GRIP-1 in the
nuclear receptor-independent functions of this coactivator.
We tested the hypothesis that MEF2 primary and secondary
cofactors are necessary for skeletal myogenesis by chemical-
mediated inhibition of methyltransferase activity and tet-reg-
ulated antisense RNA-mediated inhibition of CARM1 expres-
sion. This provided both a ”blunt“ and ”directed“ approach to
investigating methyltransferase function in skeletal muscle.
The blunt approach involved using the methyltransferase in-
hibitor adenosine dialdehyde, which inhibits all AdoMet-de-
pendent methyltransferases. Adenosine dialdehyde treatment
blocks morphological and biochemical muscle differentiation,
which is concordant with (i) the data demonstrating arginine
methyltransferase-mediated coactivation of MEF2-dependent
transcription/activity in an SRC-2/GRIP-1-dependent manner
and (ii) the critical role of MEF2 in contractile protein tran-
scription and differentiation. These data suggest that an accu-
mulation of methyl-accepting substrates in hypomethylated
states results in a block in the signal transduction pathways
that induce differentiation. Furthermore, it has been demon-
strated that the majority of hypomethylated substrates after
adenosine dialdehyde treatment are substrates of the arginine-
specific methyltransferase PRMT1, which prefers substrates
rich in glycine and arginine. These substrates include many
proteins involved in RNA binding/processing, signal transduc-
tion, and transcription. Whether the effect of adenosine dial-
dehyde on skeletal myogenesis was due to the specific inhibi-
tion of CARM1 or other AdoMet-dependent methyltransferases
cannot be discerned from these experiments. This question was
addressed by a more targeted approach involving tet-off-induc-
ible CARM1 antisense RNA expression as a ”tool“ to selectively
inhibit CARM1 expression and function. CARM1 antisense
expression abrogates the expression/induction of CARM1,
MEF2, GRIP-1, and myogenin; these proteins are crucial reg-
ulators of skeletal muscle differentiation.
The blunt and targeted approaches to the ablation of CARM1
activity in muscle cells highlighted that inhibition of myogen-
esis occurred downstream of MyoD expression (RNA and pro-
tein). It seems plausible that CARM1 activity may be necessary
for the downstream functions of MyoD and the activation of the
MyoD-dependent signal cascade. Future studies will examine
targets of CARM1 activity in muscle cells and the effects of
CARM1 on MyoD-mediated transcription.
CARM1 is expressed in the neural fold, neural tube, and
somites in 8.25–8.75-day postcoitus embryos. The spatial and
temporal expression pattern of CARM1 shows similarity to
that of MEF2 expression during mouse embryogenesis. For
example, MEF2A, MEF2C, and MEF2D are detected in
somites, and MEF2A is expressed in the brain and neural fold.
The similarities in the spatiotemporal expression patterns of
MEF2 and CARM1 are consistent with the function of the
methyltransferase as a cofactor of MEF2. Expression of
CARM1 in somites, which are the precursors to the skeletal
muscle lineage, is also concordant with abundant expression of
CARM1 mRNA and protein in muscle cells in culture. Further-
more, the early expression of CARM1 in somites during embry-
ogenesis suggests that the secondary cofactor has a functional
role in the hierarchical cascade of skeletal muscle differentia-
tion during embryogenesis.
The MEF2 family is encoded by four independent genes,
mef2a, mef2b, mef2c, and mef2d (28). Skeletal muscle differen-
tiation and the activation of myogenic specific gene expression
involve the concerted action of bHLH factors (e.g. MyoD and
myogenin) and the MADS protein MEF2 (18, 24–27). The re-
cruitment of CARM1 during MEF2-dependent activation of
muscle creatine kinase expression and its function as an MEF2
cofactor suggest that arginine methylation of histone (e.g. his-
tone H3) and non-histone (e.g. MyoD, myogenin, and MEF2)
targets potentiates the process of differentiation. Current stud-
ies are focused on identifying the specific targets of the meth-
yltransferases in skeletal muscle cells.
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